Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Announces Positive Results in CK1-Delta Alzheimer's Program

Premium

Proteome Sciences announced this week positive results from research testing several compounds as inhibitors against the candidate Alzheimer's drug target casein kinase 1 delta, or CK1δ.

The company said that it has filed intellectual property covering the results and begun optimizingthe tested compounds and testing them in an in vivo model system. Upon further lead optimization, which it hopes to complete by the middle of 2012, the company aims to license the research to a pharmaceutical firm as a drug-discovery program.

CK1δ has been shown to co-localize with the Alzheimer's protein biomarker tau, suggested that it may play some role in abnormal processing and phosphorylation of tau.

Proteome Sciences also noted that due to "increased commercial and academic interest focusing on tau protein," it has expanded its mass spec-based tau phosphorylation assay to cover ten phosphosites, including several CK1δ specific sites.

The company first launched the assay in July 2010, offering coverage of four tau phosphosites (PM 7/16/2010).

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.